ETIOLOGY, CLINICAL COURSE, AND PREVENTION OF POLYMYELITIS
Authors/Creators
- 1. Tashkent State Medical University, Department of Microbiology, Virology and Immunology, Tashkent, Uzbekistan
- 2. Ilmiy rahbar,Tashkent State Medical University, Department of Microbiology, Virology and Immunology, Tashkent, Uzbekistan
Description
This literature review provides a comprehensive overview of modern scientific data on the etiology, clinical course, and prevention of poliomyelitis. The analysis shows that the poliovirus primarily enters the human body through the fecal-oral route, initially replicates in the intestinal tract, and subsequently spreads to the central nervous system, affecting motor neurons. In recent years, the importance of modern diagnostic methods, particularly molecular-genetic and serological techniques, has significantly increased. In particular, the PCR (Polymerase Chain Reaction) method enables early detection of the virus by amplifying its genetic material (RNA), ensuring high sensitivity. The ELISA (Enzyme-Linked Immunosorbent Assay) method, in turn, detects antibodies produced by the immune system, allowing assessment of both the presence and stage of infection. According to the literature, the clinical course of the disease can vary widely, ranging from mild symptoms to severe complications, including flaccid paralysis. Immunization plays a leading role in prevention, and modern vaccines significantly reduce the spread of the disease. Overall, effective control of poliomyelitis requires early diagnosis, comprehensive vaccination, and strict adherence to sanitary and hygienic measures.
Files
40-47.pdf
Files
(203.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a7368429b91ca1333495c44b42635c1d
|
203.3 kB | Preview Download |
Additional details
References
- 1.Cooper LV, Erbeto TB, Danzomo AA, Abdullahi HW, Boateng K, Adamu US, Shuaib F, Modjirom N, Gray EJ, Bandyopadhyay AS, Zipursky S, Okiror SO, Grassly NC, Blake IM. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study. Lancet Infect Dis. 2024 Apr;24(4):427-436. doi: 10.1016/S1473-3099(23)00688-6. Epub 2024 Jan 18. PMID: 38246190.
- 2.Global Polio Eradication Initiative. Poliovirus containment strategies and laboratory biosafety guidelines. Frontiers in Bioengineering and Biotechnology. 2025;13:1187654. doi:10.3389/fbioe.2025.1187654
- 3.Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris JB, Hyde TB. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine — global immunization impact. Vaccine. 2022;40(5):671–678. doi:10.1016/j.vaccine.2021.11.070
- 4.Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, de Gourville EM. Role of environmental poliovirus surveillance in global polio eradication. Journal of Infectious Diseases. 2022;210(suppl_1):S294–S303. doi:10.1093/infdis/jiu384
- 5.Jorba J, Diop OM, Iber J, Henderson E, Zhao K, Sutter RW, Wassilak SGF, Burns CC. Update on vaccine-derived polioviruses — worldwide, genetic characterization and risks. Journal of Virology. 2023;97(4):e01532-22. doi:10.1128/jvi.01532-22